secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001104659-24-088722
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio reports Q2 2024 net loss of $12.7M, cash of $188.4M; plans Phase 2 starts for tibulizumab
--------------------------------------------------------------------------------

- Net loss of $12.7M ($0.17/share) vs $44.9M ($1.31/share) in Q2 2023; reduction driven by prior-year acquisition costs.
- Cash, cash equivalents and investments of $188.4M as of June 30, 2024, including $112.5M from April private placement; sufficient through 2027.
- Tibulizumab Phase 2 study in systemic sclerosis expected to start in Q4 2024; Phase 2 in hidradenitis suppurativa expected in Q2 2025.
- CEO Robert Lisicki appointed in April 2024; founding CEO Dr. Someit Sidhu remains on Board.
- R&D expenses were $5.5M in Q2 2024, down from $28.2M in Q2 2023 due to prior-year tibulizumab acquisition from Lilly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924088722/0001104659-24-088722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924088722/tm2411301d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer